SecBot SecBot

NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001979414 Biotech & Drug Discovery
$3.30 +0.03 (+0.92%)
Oct 26 4:00 PM ET · prev $3.27
Market cap
$87.8M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$17.50
+430% · range $13.00–20.00
Next earnings
Nov 12
in 17 days · EPS est. −$0.27
1 year
−60.0%
from $8.24 · Oct 27
30 days
+4.4%
from $3.16
52-week range
$2.53–11.83
−72% from high · low Oct 8
Avg volume 20D
153.6K
shares / day
Short interest
757.7K
≈2.5% of shares · +45.1%
Days to cover
3.9
at average volume
Insider net
+$1.1M
5 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 11 reports · 90 days
Balance 2 bearish · 4 bullish · 2 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/11 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH NeOnc Technologies is executing a $15M registered direct offering, selling shares, pre-funded warrants, and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • B Apr 2 to Apr 10 5 days of insider buys: $290.2K by 3 insiders, avg $5.67
  • B Apr 23 to May 1 4 days of insider buys: $186.2K by 3 insiders, avg $4.60
  • B Aug 14 to Aug 18 3 days of insider buys: $318.4K by 2 insiders, avg $4.36
  • R Sep 10 NeOnc Technologies is executing a $15M registered direct offering, s…
  • B Sep 11 to Sep 15 3 days of insider buys: $351.4K by 3 insiders, avg $3.58
  • S Sep 15 1 insider sell $16.8K at $3.36
  • A Sep 24 Roth Capital initiates
  • X Sep 30 Short interest jumps 45.1% to 757.7K

Signal stack

Where each data set points today.

  • InsidersBULLISH

    5 insiders bought $1.1M at an average $4.36. 1 insider sold $16.8K. Price is 24% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.210 → −$0.273 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +45.1% to 757.7K shares. 3.9 days to cover, ≈2.5% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED504,171$2.3M
GEODE CAPITAL MANAGEMENT, LLCADD166,120$752.8K
VANGUARD FIDUCIARY TRUST COADD91,480$414.4K
NORTHERN TRUST CORPADD35,871$162.5K
MARSHALL WACE, LLPADD21,784$98.7K
MORGAN STANLEYTRIM15,647$70.9K
WELLS FARGO & COMPANY/MNADD2,000$9.1K
UBS Group AGDOUBLED1,731$7.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy3Buy6Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +430%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 24, 2026Roth Capital
INITIATE
INITIATEBuy
Sep 8, 2026BTIG
REITERATE
REITERATEBuy
May 26, 2026BTIG
REITERATE
REITERATEBuy
May 19, 2026Alliance Global Partners
INITIATE
INITIATEBuy
May 18, 2026Maxim Group
INITIATE
INITIATEBuy

Insider ledger

Form 4
$1.1M
bought · 5 insiders
$16.8K
sold · 1 insider
−24.4%
vs their $4.36 cost
DateInsiderTypeValue
Sep 15, 2026
Heshmatpour Amir F
CEO, President
BUY$115.4K
Sep 15, 2026
GARNETT KEITHLY
CFO
SELL$16.8K
Sep 14, 2026
GARNETT KEITHLY
CFO
BUY$1.0K
Sep 14, 2026
CHEN THOMAS C
CEO
BUY$20.0K
Sep 14, 2026
Heshmatpour Amir F
CEO, President
BUY$59.4K
Sep 11, 2026
Heshmatpour Amir F
CEO, President
BUY$135.6K
Sep 11, 2026
CHEN THOMAS C
CEO
BUY$20.0K
Aug 18, 2026
Heshmatpour Amir F
CEO, President
BUY$49.9K

Earnings setup

Estimates
Nov 12
reports in 17 days
−$0.27
EPS estimate, this quarter
−30%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.27-$0.47–-$0.08+18.7%$0.00
Next Q-$0.33-$0.47–-$0.18+0.8%$0.00
Current FY-$1.30-$1.90–-$0.74+3.5%$0.00
Next FY-$1.09-$1.73–-$0.49-8.3%$0.00

Short side

FINRA· Sep 30, 2026
757,739
shares short
+45.1%
vs prior settlement
3.9
days to cover
≈2.5%
of shares outstanding
Trading halts
Aug 12, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Other
🔒 Fresh data, subscribers only
Oct 22, 2026 SEC
NeOnc Technologies filed an 8-K reporting three press releases: early clinical improvement in a single pediatric…
8-K — Impact 3/10
Oct 15, 2026 SEC
NeOnc Technologies announced the resignation of director Dr. Steven Giannotta and the appointment of Ali Alabedin…
8-K — Impact 3/10
Sep 18, 2026 SEC
Three insiders at NeOnc Technologies traded within a week of a dilutive $15M offering. CEO Amir Heshmatpour made two…
CLUSTER — Impact 5/10
Sep 15, 2026 Insider
Heshmatpour Amir F bought 35,000 shares
CEO, President @ $3.30 ($115.4K)
Sep 15, 2026 Insider
GARNETT KEITHLY sold 5,000 shares
CFO @ $3.36 ($16.8K)
Sep 14, 2026 Insider
GARNETT KEITHLY bought 257 shares
CFO @ $3.89 ($1.0K)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — DOUBLED
504,171 shares ($2.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
NTHI Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 23, 2026
Press release
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
NeOnc (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, an important technical signal before its upcoming catalysts...
Oct 22, 2026
Press release
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight
NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the…
Oct 22, 2026
Press release
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy...
Oct 21, 2026
Press release
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
NeOnc (Nasdaq: NTHI) signed a MoU with the Department of Health – Abu Dhabi to support research and clinical capability in oncology and CNS...

SecBot reports

34 filings · 1 press release · 7 bullish · 12 bearish · 4 mixed · 11 neutral
All NTHI filing & press-release reports (35)